CD19 CAR-T治疗中枢神经系统复发或难治性急性淋巴细胞白血病:五项临床试验汇总数据的回顾性分析
该事后分析汇总五项临床试验中195例1-29岁复发或难治性CD19阳性急性淋巴细胞白血病/淋巴细胞淋巴瘤患者,接受CD19 CAR-T(tisagenlecleucel或huCART19)治疗。CNS阳性与CNS阴性患者在28天完全缓解率、2年无复发生存和总生存上无显著差异,神经毒性和细胞因子释放综合征发生率与严重程度亦无显著差异;孤立CNS受累者2年总生存显著优于合并骨髓受累者。
核心结论
- Tisagenlecleucel和huCART19可清除CNS病变并维持持久缓解,且不增加严重神经毒性风险,但需注意治疗时机和疾病控制以降低风险。
研究设计与样本
- 事后分析,纳入五项临床试验(Pedi CART19、13BT022、ENSIGN、ELIANA、16CT022)中195例1-29岁复发或难治性CD19阳性急性淋巴细胞白血病或淋巴细胞淋巴瘤患者。
- 154例接受tisagenlecleucel,41例接受huCART19;按复发时或CAR-T输注前12个月内CNS状态分层为CNS阳性或CNS阴性。
- CNS阳性患者进一步按骨髓形态学受累分为合并骨髓和CNS受累或孤立CNS受累。
- 试验要求入组和输注时CNS疾病得到控制,排除急性神经毒性(>1级)或被认为增加神经毒性风险的脑实质病变。
主要发现
- 195例中66例(34%)为CNS阳性,129例(66%)为CNS阴性,43例(22%)为孤立CNS受累。
- CNS阳性组中位随访39个月(IQR 25-49),CNS阴性组36个月(IQR 18-49)。
临床怎么用
- 对于有CNS复发或难治史的CD19阳性B-ALL患者,可考虑使用tisagenlecleucel或huCART19,但需确保入组和输注时CNS疾病得到控制。
- 孤立CNS受累患者可能获得更优的2年总生存,治疗决策时可参考骨髓受累状态。
局限性
- 为事后分析,非预设亚组分析,证据级别有限。
- 试验排除了急性神经毒性(>1级)或高风险脑实质病变患者,结果可能不适用于此类人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: CNS relapse of acute lymphocytic leukaemia is difficult to treat. Durable remissions of relapsed or refractory B-cell acute lymphocytic leukaemia have been observed following treatment with CD19-directed chimeric antigen receptor (CAR) T cells; however, most trials have excluded patients with active CNS disease. We aimed to assess the safety and activity of CAR T-cell therapy in patients with a history of CNS relapsed or refractory B-cell acute lymphocytic leukaemia. METHODS: In this post-hoc analysis, we included 195 patients (aged 1-29 years; 110 [56%] male and 85 [44%] female) with relapsed or refractory CD19-positive acute lymphocytic leukaemia or lymphocytic lymphoma from five clinical trials (Pedi CART19, 13BT022, ENSIGN, ELIANA, and 16CT022) done at the Children's Hospital of Philadelphia (Philadelphia, PA, USA), in which participants received CD19-directed CAR T-cell therapy between April 17, 2012, and April 16, 2019. The trials required control of CNS disease at enrolment and infusion and excluded treatment in the setting of acute neurological toxic effects (>grade 1 in severity) or parenchymal lesions deemed to increase the risk of neurotoxicity. 154 patients from Pedi CART19, ELIANA, ENSIGN, and 16CT022 received tisagenlecleucel and 41 patients from the 13BT022 trial received the humanised CD19-directed CAR, huCART19. We categorised patients into two strata on the basis of CNS status at relapse or within the 12 months preceding CAR T-cell infusion-either CNS-positive or CNS-negative disease. Patients with CNS-positive disease were further divided on the basis of morphological bone marrow involvement-either combined bone marrow and CNS involvement, or isolated CNS involvement. Endpoints were the proportion of patients with complete response at 28 days after infusion, Kaplan-Meier analysis of relapse-free survival and overall survival, and the incidence of cytokine release syndrome and neurotoxicity. FINDINGS: Of all 195 patients, 66 (34%) were categorised as having CNS-positive disease and 129 (66%) as having CNS-negative disease, and 43 (22%) were categorised as having isolated CNS involvement. The median length of follow-up was 39 months (IQR 25-49) in the CNS-positive stratum and 36 months (18-49) in the CNS-negative stratum. The proportion of patients in the CNS-positive stratum with a complete response at 28 days after infusion was similar to that in the CNS-negative stratum (64 [97%] of 66 vs 121 [94%] of 129; p=0·74), with no significant difference in relapse-free survival (60% [95% CI 49-74] vs 60% [51-71]; p=0·50) or overall survival (83% [75-93] vs 71% [64-79]; p=0·39) at 2 years between the two groups. Overall survival at 2 years was significantly higher in patients with isolated CNS involvement compared with those with bone marrow involvement (91% [82-100] vs 71% [64-78]; p=0·046). The incidence and severity of neurotoxicity (any grade, 53 [41%] vs 38 [58%]; grade 1, 24 [19%] vs 20 [30%]; grade 2, 14 [11%] vs 10 [15%]; grade 3, 12 [9%] vs 6 [9%], and grade 4, 3 [2%] vs 2 [3%]; p=0·20) and cytokine release syndrome (any grade, 110 [85%] vs 53 [80%]; grade 1, 12 [9%] vs 2 [3%]; grade 2, 61 [47%] vs 38 [58%]; grade 3, 18 [14%] vs 7 [11%] and grade 4, 19 [15%] vs 6 [9%]; p=0·26) did not differ between the CNS-negative and the CNS-positive disease strata. INTERPRETATION: Tisagenlecleucel and huCART19 are active at clearing CNS disease and maintaining durable remissions in children and young adults with CNS relapsed or refractory B-cell acute lymphocytic leukaemia or lymphocytic lymphoma, without increasing the risk of severe neurotoxicity; although care should be taken in the timing of therapy and disease control to mitigate this risk. These preliminary findings support the use of these CAR T-cell therapies for patients with CNS relapsed or refractory B-cell acute lymphocytic leukaemia. FUNDING: Children's Hospital of Philadelphia Frontier Program.
引用
- Leahy AB, Newman H, Li Y, et al. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. Lancet Haematol. 2021. PMID: 34560014. doi:10.1016/S2352-3026(21)00238-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。